Author Affiliation: Department of Dermatology, University of California, San Francisco.
Sentinel node biopsy may be a useful prognostic tool for a subset of melanomas of intermediate stage.1 The Perspective by Benjamin and Froom,2 however, highlights the problems with its use in a different situation: a patient with an early stage IA melanoma, 0.5 mm in depth, without ulceration or a high mitotic rate. This patient has an excellent prognosis, with a 98% expected survival at 15 years and a greater than 97% chance of having clear lymph nodes.3,4
Linos E. Sentinel Lymph Node Biopsy in Early MelanomaComment on “What the Surgeon Should Have Said to My Patient With Thin Malignant Melanoma”. Arch Intern Med. 2012;172(12):907. doi:10.1001/archinternmed.2012.1905